Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Share-based Compensation (2022 - 2025)

Historic Share-based Compensation for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to $67132.0.

  • bioAffinity Technologies' Share-based Compensation fell 6384.67% to $67132.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $839442.0, marking a year-over-year decrease of 1531.08%. This contributed to the annual value of $989681.0 for FY2024, which is 3216.49% up from last year.
  • According to the latest figures from Q3 2025, bioAffinity Technologies' Share-based Compensation is $67132.0, which was down 6384.67% from $211607.0 recorded in Q2 2025.
  • bioAffinity Technologies' Share-based Compensation's 5-year high stood at $326616.0 during Q1 2025, with a 5-year trough of $26685.0 in Q2 2022.
  • Moreover, its 4-year median value for Share-based Compensation was $170254.0 (2023), whereas its average is $166156.6.
  • Per our database at Business Quant, bioAffinity Technologies' Share-based Compensation soared by 53801.39% in 2023 and then tumbled by 6384.67% in 2025.
  • Quarter analysis of 4 years shows bioAffinity Technologies' Share-based Compensation stood at $36847.0 in 2022, then surged by 536.44% to $234510.0 in 2023, then dropped by 0.18% to $234087.0 in 2024, then plummeted by 71.32% to $67132.0 in 2025.
  • Its Share-based Compensation stands at $67132.0 for Q3 2025, versus $211607.0 for Q2 2025 and $326616.0 for Q1 2025.